Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033

Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research